Tarafenacin
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Tarafenacin是M3毒蕈碱受体的选择性拮抗剂,其Ki值为0.19 nM[1].
Tarafenacin是新型的奎宁环衍生物,作为一种抗毒蕈碱药,用于治疗膀胱过度活动症.Tarafenacin对M3受体的选择性比M2受体高203倍.在小鼠离体膀胱中,10 nM和100 nM Tarafenacin可以降低最大carbachol反应.在小鼠心房制备物中,Tarafenacin稍微减弱Carbachol对心率的影响.Tarafenacin在尿液中的分布量比在心脏中的高199倍.在同等浓度范围下,Tarafenacin对膀胱显示出高度有效的拮抗作用,但对心房没有任何影响.在豚鼠模型中,Tarafenacin显著改变膀胱收缩幅度.在17.1 nmol/kg剂量下,Tarafenacin抑制了25%自发性膀胱收缩[1].
参考文献:
[1] Salcedo C, Davalillo S, Cabellos J, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. British journal of pharmacology, 2009, 156(5): 807-817.
Storage | Store at -20°C |
M.Wt | 408.39 |
Cas No. | 385367-47-5 |
Formula | C21H20F4N2O2 |
Solubility | Soluble in DMSO |
Chemical Name | [(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]carbamate |
SDF | Download SDF |
Canonical SMILES | C1CN2CCC1C(C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |